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EGF as a New Therapeutic Target for Medulloblastoma 
Metastasis
Jennifer Rico-Varela1,#, Tanya Singh1,#, Sean McCutcheon1, and Maribel Vazquez1,*
1Department of Biomedical Engineering, The City College of New York, 160 Convent Avenue, 
ST-403D, New York, NY 10031
Abstract
Medulloblastoma (MB) is a malignant pediatric brain tumor known for its aggressive metastatic 
potential. Despite the well-documented migration of MB cells to other parts of the brain and spinal 
column, MB chemotaxis is poorly understood. Herein, we examined the in vitro migratory and 
cellular responses of MB-derived cells to external signaling of Epidermal Growth Factor (EGF), 
hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF-BB), and the stromal cell-
derived factors 1-alpha (SDF-1). Experiments utilized transwell assays and immunocytochemistry 
to identify receptor activation in MB migration, and used a microfluidic platform to examine 
directionality, trajectory, and gradient-dependence of motile cells. Data illustrates that MB-derived 
cells respond strongly to EGF in a dosage and gradient-dependent manner with increased EGF-R 
activation, and show that high EGF gradient fields cause an increased number of cells to migrate 
longer directed distances. Our results provide evidence that EGF and its receptor play an important 
role than previously documented in MB chemotactic migration than previously documented and 
should be considered for developing migration-target therapies against MB metastasis.
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INTRODUCTION
Medulloblastoma (MB) is a family of highly-invasive tumors most commonly diagnosed in 
the pediatric central nervous system (7, 28, 38, 41, 50). While clinical treatments have more 
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than doubled the overall 5-year survival rate to upwards of 60% (16, 28, 44, 52), additional 
therapies are needed to target the aggressive MB migration that is uncharacteristic of other 
brain tumors, but is a hallmark of MB recurrence, metastasis, and 
radioresistivity (13, 21, 24, 28, 41, 55, 61, 70). The migration of cancer cells within the CNS is 
decidedly complex, affected by cellular interactions with heterogeneous extracellular matrix 
(ECM) as well as mixed cellular responses to concentration fields of 
biomolecules (1, 14, 19, 60, 65). However, the mechanisms behind the migration of MB-
derived cells along CNS gradients of biomolecular concentration, or chemotaxis, remain 
understudied and incompletely understood (14, 28). Particular complexities arise in MB, 
because chemoattractant fields that rouse cells away from primary tumors can be secreted by 
healthy or transformed distant and neighboring cells (1, 3, 9, 34, 58, 76). Further, clinical studies 
have illustrated that the spread of MB cells occurs predominantly to the spinal column via a 
combination of two-dimensional (2D) and three-dimensional (3D) 
movements (6, 51, 67, 77, 83). Such spreading results from tumor cells that drop into the 
cerebrospinal fluid and tend to seed in parts of the spine (53, 74, 77, 79, 84). As a result, the 
movement of MB cells on the surface of the spinal column can be examined on 2D substrata 
to plausibly physiologically approximate the metastatic behavior of these pediatric brain 
tumors.
Traditional cell migration studies have looked to transwell (27, 48, 81) and wound healing 
assays (36, 54, 78) to report numbers of cells that become motile in response to external 
signaling from growth factors, such as Epidermal Growth Factor (EGF) and Platelet-Derived 
Growth Factor (PDGF) (4). However, chemotaxis is becoming more-commonly examined 
via the physical microenvironment of the cell, where dynamic concentration fields facilitate 
ligand-receptor bindings which initiate signal transduction cascades (1, 8, 59). Here, precise 
manipulation of the cell microenvironment has been facilitated by the wide-adaptation of 
benchtop microfluidic devices (26, 27, 29), which enable multifaceted evaluation of cell 
migratory behaviors in lieu of cell numbers alone. A large number of laboratories have 
demonstrated concentration- and concentration gradient-dependent behavior of non-
cancerous cells, such as fibroblasts (33), retinal progenitor cells (69) and keratinocytes (64), as 
well as tumors found in breast (57), colon (17) and CNS cancers (2). Our own laboratory has 
illustrated that select populations of cells derived from CNS tumors can respond acutely via 
migration to ultra-low concentration gradients of select chemoattractants (2, 14, 33), while 
others have shown greater chemotactic response with specific dosage (3, 49, 56). Microfluidic 
analysis is, thus, well positioned to meaningfully aid in the development of migration-
targeted therapies for MB via insight of migratory parameters relevant to metastasis, such as 
cell distance traveled, motility, gradient-sensitivity, ECM interaction and numerous others.
In this work, we examine MB migratory behavior in response to external signaling from 4 of 
the most extensively studied chemoattractants of CNS tumors using benchtop assays and 
microfluidics: Epidermal Growth Factor (EGF), Platelet-derived Growth Factor (PDGF), 
Hepatocyte Growth Factor (HGF), and Stromal Derived Growth Factor (SDF-1 or 
CXCL12). Our results illustrate that MB-derived cells exhibit gradient-dependent behavior 
in EGF fields, which are able to guide MB along longer migration distances with superior 
directionality and increased receptor activation. These results distinguish EGF as a principal 
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In vitro cell culture was maintained using Daoy cell line (ATCC, Cat. No.HTB-186) (14, 60), 
Eagle's Minimal Essential Medium (EMEM) (VWR, Cat. No.12001-582) supplemented 
with 10% fetal bovine serum (VWR, Cat. No.45000-734), 2% L-glutamine (VWR, Cat. No.
45000-676) and 1% Penicilin-Streptomycin (VWR, Cat. No.45000-650). Intact monolayers 
were maintained and harvested cells were seeded onto sterile polystyrene tissue culture 
flasks (VWR, Cat. No.BD353136). MB cells were incubated at 37 °C with 5% CO2 with 
cell medium changed every 2 days. Cell migration experiments were initiated with cells that 
were inserted into microchannel after MB cells reached 80% confluence.
Cell Migration Assay
The Boyden chamber assay (2, 14) was used to measure the number of MB cells that 
migrated towards different concentrations of external growth factors. This widely-used assay 
consists of two compartments filled with EMEM medium and separated by an 8 micron-
porous membrane (VWR, Cat. No.62406-198), as shown in Figure 1.A. MB cells were 
seeded in the upper compartment and were allowed to migrate through the porous membrane 
into the lower compartment for 6 hours at 37 °C in a 5% CO2 incubator. Approximately 
1×106 cells/mL were seeded in 300μl of EMEM complete medium (EMEM with FBS) in 
each upper chamber, while 700μl of serum-free medium (EMEM only) was pipetted into 
each lower chamber. Lower chambers also contained concentrations of 1, 10, 100, and 1000 
ng/mL of EGF (Life Technologies Corporation, Cat. No.E3476); HGF (R&D Systems, Cat. 
No.2207-HG/CF); PDGF-BB (R&D Systems, Cat. No.220-BB-010); and finally SDF-1 
(PreporTech, Cat. No.250-20A). All growth factor solutions were diluted in EMEM serum-
free medium using serial dilution. After 6 hours of incubation, the membrane was fixed and 
stained with fixative solutions (VWR, Cat. No. B4132-11A), which stained the cell 
cytoplasm and nuclei. The number of cells that migrated to the underside of each membrane 
was determined by using the convectional checkerboard analysis (2, 14, 82).
Immunostainning of Receptors
MB cells were plated at a concentration of 1×103 cells/mL in EMEM complete, on 
borosilicate glass well plates (Lab-Tek, Cat. No.155383). The cells were incubated for 2 
hours at 37°C in 5% CO2 to facilitate attachment. Adhered cells were exposed to ligands at 
concentrations that resulted in the largest numbers of motile cells in the transwell assay 
results. At 37°C, each cell plate was exposed to 5 minutes of: 100ng/mL EGF (Life 
Technologies, Cat. No.PGH0311), 100ng/mL CXCL12 (Life Technologies, Cat. 
No.PHC1364), 10ng/mL HGF (Life Technologies, Cat. No.PHG0324), and 100ng/mL 
PDGF-BB (Life Technologies, Cat. No.PHG0044). The supernatant was then aspirated and 
each well was rinsed 3 times with 0.5 mL phosphate buffered saline solution (PBS), (Sigma-
Aldrich, Cat. No.D8537). Each well was fixed using 10% paraformaldehyde (Sigma-
Aldrich, Cat. No.HT501128) for 10 minutes, and rinsed twice with PBS. The samples were 
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permeabilized using a 1% solution of Triton-X (Sigma-Aldrich, Cat. No.X100) and 
0.1%BSA in PBS solution for 10 minutes, then blocked for 60 minutes with 1% BSA in 
PBS blocking solution and rinsed twice with the same blocking solution.
Samples were then exposed to the primary antibody for each receptor studied for 2 hours at 
22°C: 5μg/mL anti-EGFR (Life Technologies, Cat. No.700308), 5μg/mL anti-CXCR4 (Life 
Technologies, Cat. No.35-8800), 2μg/mL anti-c-Met (Millipore, Cat. No.072242), and 
3μg/mL anti-PDGFR (Life Technologies, Cat. No.701142). Each well was rinsed 3 times 
with 1% BSA blocking solution. A fluorescent secondary anti-rabbit IgG (Millipore, Cat. 
No.AP132F) was used for EGFR, c-Met, and PDGFR samples, and a fluorescent anti-mouse 
secondary antibody (Millipore, Cat. No.MAB1976) was used for CXCR4 samples. All 
samples were exposed to the secondary antibody at a concentration of 5μg/mL for 30 
minutes at 22°C, and then rinsed twice with blocking solution. Nuclear staining (Life 
Technologies, Cat. No.R37605) was performed for 20 minutes at 22°C, after which the 
samples were rinsed twice with PBS and covered in glycerol (Life Technologies, Cat. No.
15514-011) for preservation. In addition, the expression of EGFR was measured at different 
time points of 0, 14, 22, 36, and 42 hours. The immunocytochemistry assay was performed 
as described above using goat-anti mouse IgG secondary antibody (Life Technologies, Cat. 
No. A-11005) for EGFR.
Bridged μLane and Experimental Set up
Our microfluidic device, the μLane, was utilized to image the real-time migratory responses 
of individual MB cells within microenvironments of defined EGF and SDF-1 gradient 
profiles. The bridged μLane system operates via a combination of uniaxial bulk convection 
and diffusion to achieve controlled chemical concentration gradients over time, as described 
previously (2, 32, 33). This mass transfer mechanism termed as convective-diffusion has been 
widely-studied by several groups for bioengineering applications, to determine the transport 
of differently sized solutes and proteins through the walls of capillaries (11, 12, 20) and 
arteries (25, 30, 39, 66, 80), skeletal muscle fibers (31, 35, 45), and intervertebral discs (18, 62, 63). 
The two-dimensional mass transport of ligands within the microsystem was modeled via 
finite-element-analysis (FEM) in Matlab 7.7 (MathWorks, Natick, MA) and verified 
experimentally as described previously by our group (32, 33).
The framework of the μLane system consists of two layers of Polydimethylsiloxame 
(PDMS) (Fisher Scientific, Cat. No.NC9644388) bonded to a glass slide using ozone gas. 
The first layer of PDMS consists of a closed microchannel of 100μm-width and 1.3cm-
length with a volume of 0.1μL, which connects two fluidic reservoirs of 9μL each, called the 
source (SRR) and the sink (SKR) reservoir. The second layer of PDMS consists of two 
chambers of 170μL each, called the source (SRC) and the sink (SKC) chamber, connected 
by an open, hemispherical bridge channel to maintain the hydrostatic equilibrium of the 
system (32, 33, 69). Both chambers are vertically and fluidically connected with both 
reservoirs (Figure 3).
The μLane system works by using the larger volumes of the SRC, SKC and bridge channel 
on the second layer of PDMS to generate concentration gradients within the smaller volumes 
of the SRR, SKR and microchannel on the first layer (14, 32, 33, 69). After inserting cells 
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along the microchannel length, the cell culture media is used to fill the SRR, SKR, SRC, 
SKC, and the bridge channel. The ligand solutions (EGF or SDF-1) are then manually 
inserted drop-wise into the SRC until the solution makes contact with the cell culture media 
solution within the bridge channel and SKC to initiate the molecular transport within the 
system. The small differences in the density of the reagents and in the liquid levels in the 
SRR and SKR generate hydrostatic pressure differences that initiate an ultra-low bulk flow 
within the microchannel in the first layer (32, 33, 69). This minuscule bulk flow was measured 
to be 0.37 μm/sec using fluorescent beads, as described previously (32). Such a low bulk 
flow facilitates the transport of ligand solutions from the SRR to the SKR, to accelerate the 
time required to attain a steady-state gradient profile of ligand solutions along the 13-mm 
length of the microchannel. In the absence of this bulk flow, the transport of our reagent via 
diffusion alone would require over 470 hours to reach a steady-state distribution within the 
length of the μLane instead of the 18 hours measured, as reported by our group (14, 32). We 
note that because the time required for the overall system to reach steady-state is much 
larger than the time needed for steady-state concentration gradients to be generated within 
the μLane system alone. Thus, the operation of the system is ‘best’ described as ‘quasi-
steady-state’ (5, 10, 40, 68, 71, 73). However, because this work focuses exclusively on smaller 
time scales of the microchannel only, the term steady-state would be used for simplicity. 
Mathematical models of reagent transport within our μLane system were performed via 
MatLab to determine the steady-state concentration distribution as seen in Figure 4.A. The 
initial EGF or SDF-1 concentration within the SKC, SKR, microchannel and SRR was set to 
0-ng/mL, as per absence of ligand. The initial ligand concentration within the SRC was set 
to 100-ng/mL to reflect the sample concentration used during experiments. These boundary 
conditions were solved using Equation (1), as shown below (32),
(1)
Where C (ng/mL) is ligand concentration, t (hours) is time, u (μm/sec) is fluid velocity, and 
D (cm2/s) is diffusion coefficient, or diffusivity, of the reagent molecule. Experimental 
validation was also performed using fluorescently labeled Dextran (~ MW 10KDa), to 
confirm steady-state is reached in our system after 18 hours, and is maintained for several 
days (14, 32).
For our experiments, the μLane system was coated with 10-μg/mL of laminin (Becton, 
Dickinson and Company, Cat. No.354232) (14, 60), and allowed to gel for one hour at room 
temperature (25°C) under sterile conditions. Unbound laminin was aspirated and cells were 
manually seeded into the microchannel using a 1-mL syringe (VWR, Cat. No.BD309659). A 
cell solution (1×106 cells/mL) was injected into the SRR and SKR. Cells were allowed to 
adhere and visibly spread prior to the initiation of the experiment as illustrated in Figure 
3.D. Finally the bridge channel was loaded with EMEM complete medium to connect the 
SRC and SKC, initiating the system. In this work, EGF (100-ng/mL) or SDF-1 (100-ng/mL) 
was individually loaded drop-wise into the SRC and allowed to reach steady state in the 
microchannel for 18 hours at 37°C (32), prior to imaging of MB cell migration within this 
precise biochemical environment; therefore, all data is collected within steady-state 
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concentration gradient fields for 24 hours. Our group has previously showed that MB cells 
migrate and proliferate in-vitro until 72 hours in the μLane system (14).
Statistics
One-way ANOVA and Post Hoc Test (Tukey) were used to analyze the data using IBM 
SPSS Statistics Program (IBM Corp., Released 2011, version 20.0. Armonk, NY). A one-
way ANOVA test at a 95% confidence interval was performed for statistical significance 
across growth factors. The Post Hoc Test (Tukey) was performed to determine the disparity 
among different groups. Only p-values <0.05 were considered statistically significant. 
Unpaired student's t-test at a 95% confidence interval was implemented to determine 
significance of relative receptor expression using IBM SPSS Statistics Program (IBM Corp., 
Released 2011, version 20.0. Armonk, NY).
Imaging and Processing
Transmitted light microscopy images were obtained using an inverted microscope (Nikon 
TE2000) and a cooled CCD camera (CoolSNAP EZ CCD Camera, Photometrics, Tucson, 
AZ) with a 20X objective magnification (Nikon Plant 20X, Morrell Instrument Company 
Inc., Melville, NY). Fluorescent imaging was performed using Leica CLSM confocal 
microscope and a Zeiss LSM 710 confocal microscope, both at 63x magnification with oil 
immersion objective. Image J was utilized to track cells and process images (Chemotaxis 
and Migration Tool plugin (ImageJ 1.46r) (14, 15). Fluorescence intensity was measured 
using an average over the entire cell area via ImageJ. Transmitted light image data was 
analyzed using Nikon software (Nikon Instrument Element 2.30 with 6D module, Morrell 
Instrument Company Inc., Melville, NY) and ImageJ (NIH) Software. Bright field images of 
the microchannel were automatically captured every hour for 24 hours at every 1000 
microns in the y-direction of the μLane, followed by cell tracking (ncells~180 cells) and 
analysis. Lastly, the cell tracking software was used to develop Wind-Rose plots (33, 69) of 
cell trajectories in response to EGF and SDF-1 gradient fields, over 24 hours.
RESULTS
This work examined the migratory and cellular responses of MB-derived cells in response to 
external signaling from EGF, HGF, PDGF-BB, and SDF-1.
Motility Studies
The first set of experiments measured the average numbers of MB-derived cells that 
migrated toward different concentrations of EGF, HGF, PDGF-BB, and SDF-1 through 
transmembrane assays, as illustrated in Figure 1 and Table 1. As seen, numbers of motile 
cells were statistically different in response to signaling from different concentrations of 
EGF and HGF when compared to controls (i.e. no ligand). Further, a mid-level 
concentration of 100-ng/mL of EGF was observed to attract the largest numbers of motile 
cells overall (Fig. 1.B.2). By contrast, the number of MB cells that migrated in response to 
external signaling from concentrations of SDF-1 did not exhibit statistical difference from 
controls or each other (Fig. 1.B.4). Similarly, the number of motile MB in response to 
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signaling from different concentrations of PDGF-BB did not display statistical differences 
from controls (Fig. 1.B.3).
Relative Receptor Expression
The basal expression levels of the respective receptors were then compared against their 
activation levels upon ligand stimulation. Confocal images in Figure 2 illustrate differences 
in cellular distribution of activated receptors, as well as differences in fluorescent intensity 
after ligand stimulation. As seen, basal receptor expression appears to be uniformly 
distributed throughout the cell cytosol, with lowest intensities measured for EGF-R. Upon 
ligand activation, receptor expression is increased, but remains largely distributed 
throughout the cytosol. However, EGF-R expression is also observed to be acutely 
concentrated along the outer cell membrane. Analysis of fluorescence intensity then 
represented relative receptor expression levels upon ligand-stimulation. MB stimulated with 
EGF exhibited the highest increase in receptor expression for EGF-R, with a 3.5-fold 
increase in intensity over basal EGF-R expression measured in unstimulated controls (Fig. 
2.A). By contrast, the expression of CXCR4, the receptor for SDF-1, was approximately 2-
fold higher than its basal intensity levels in cells unstimulated with ligand (Fig. 2.B), while 
no statistical difference was measured between the activation levels of c-Met, the receptor 
for HGF (Fig. 2.C), and control cells, as well as between PDGFR-BB (Fig 2.D) in ligand-
stimulated cells compared to controls. MB cells stimulated with EGF for different time 
points of 0, 14, 22, 36, and 42 hours displayed no relevant significant difference in receptor 
expression for EGF-R across time points, and were all higher than the unstimulated control 
(See supplementary Figure 1).
Migratory response to controlled concentration and gradient fields
The migratory behavior of MB was next examined using our microfluidic system, called the 
μLane and shown in Figure 3, for real-time cell imaging and analysis. The transport of EGF 
and SDF-1 along the μLane was modeled computationally, and verified experimentally as 
previously reported by our group (32). The system produced a range of concentration 
gradients along the microchannel length at steady-state, as shown in Figure 4.A (14, 33). 
Concentration gradients of this study are defined as the average difference in growth factor 
concentration (ng/mL) along the microchannel length (mm). Five orders of concentration 
gradient, G1-G5, were delineated along the microchannel as illustrated in Figure 4.A: 
10+1<G1<100 ng/(mL.mm), 100<G2<10−1 ng/(mL.mm), 10−1<G3<10−2 ng/(mL.mm), 
10−2<G4<10−3 ng/(mL.mm), and 10−3<G5<0. The lowest gradient, G5, was located near the 
source reservoir (growth factors only) and occupied approximately 1-mm-length of the 
microchannel, while the highest gradient, G1, was located near the sink reservoir and 
occupied an approximate, 3-mm-length of microchannel. Concentration gradients, G2, G3, 
and G4, occupied the remaining 9-mm-length of microchannel (distance in between the 
source and the sink reservoirs) with approximately 4 mm, 3 mm and 2 mm segments, 
respectively. Note, the core distributions of EGF and SDF-1 along the microchannel are very 
similar to one another given their respective molecular weights of 6.045 KDa and 7.9 KDa, 
and hence only one representative gradient distribution is shown. Further, cells were evenly 
distributed along all segments of the channel prior to the start of experiments.
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The migration of MB-derived cells in response to the different concentration gradient fields 
of EGF and SDF-1 were described using three parameters: (1) Fraction of motile cells, f, 
defined as the number of cells that migrated more than two cell diameters in theμLane, 
normalized by the total number of cells within the channel; (2) cell directionality, D, defined 
as the percentage of cells whose net center of mass was preferably towards the positive, x-
displacement or along the gradient direction; and (3) Average cell path length, PL, defined 
as the total distance traveled by cells.
First, the average percentage of motile cells along the entire microchannel was similar for 
both growth factors. Table 2 shows that 72.82% of MB became motile in response to EGF 
signaling, while an average 67.3% of MB became motile in response to SDF-1 concentration 
fields. Values of motile fraction varied with gradient fields, fG1-fG5, for both EGF and 
SDF-1, as shown in Table 3. As seen, the highest fraction of MB cells became motile when 
exposed to higher concentration gradient fields of EGF, G1 (f1=28.3%) and G2 (f2=18.6%), 
followed by decreasing percentages of motile cells within lower gradient fields of EGF, G3 
(f3=11.9%), G4 (f4=10.3%) and G5 (f5=3.7%). Similarly decreasing fractions of cells were 
seen to migrate in response to concentration gradient fields of SDF-1, with highest fractions 
at G1 (f1=18.2%) and G2 (f2=20%), followed by significant decreases in the fraction of 
motile cells at concentration gradient fields G3 (f3=13.8%), G4 (f4=8.7%) and G5 
(f5=6.5%). As shown in Figure 4.B, the fraction of nonmotile cells was 27.2% and 32.8%, 
when exposed to similar concentration gradients of EGF and SDF-1, respectively. Statistical 
significance was observed between concentration gradient fields of EGF while no statistical 
significant difference was found across the gradient fields of SDF-1.
Next, the average directionality of motile MB was determined by examining individual cell 
trajectories. The term directionality was previously introduced by our group as the ratio of 
the number of cells whose centroids migrated more than 80 μm to the total number of cells 
in the microchannel (33). The paths of MB cells in the presence of EGF and SDF-1 
concentration gradient fields were optically tracked within the μLane system to generate the 
representative Wind-Rose plots shown in Figure 5.A. Note that although cell trajectories are 
each positioned at a common origin for comparison, cell paths were measured along all 
microchannel segments, exposed to all gradient fields G1-G5. Representative trajectories 
illustrate that cells migrated preferentially towards lower concentration gradients of EGF 
(i.e., towards the right). By contrast, SDF-1 fields resulted in MB migration that was both 
towards and away from lower SDF gradients without preference. The directionality of 
motile cells along the entire microchannel was higher for cells stimulated with EGF (61.6%) 
than SDF-1 (44.2%), shown in Table 2. As seen, cell directionality within specific gradient 
fields, DG1-DG5, decreased with decreasing gradient for both EGF and SDF-1, shown in 
Table 3. EGF DG1 indicates that 28.3% of motile cells migrated directionally when exposed 
to G1 of EGF (i.e. within the first 3mm of channel length), while SDF DG1 denotes that only 
18.4% displayed directional migration for the same gradient field of SDF-1. The highest 
fraction of MB cells directionality was reported at higher concentration gradient fields of 
EGF, DG1 (28.3%) and DG2 (15%), followed by decreasing percentages for directionality 
within lower gradient fields of EGF, DG3 (7%), DG4 (8.6%), and DG5 (2.7%). Similarly 
decreasing fractions of directionality were reported in response to concentration gradient 
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fields of SDF-1, with highest fractions at DG1 (18.4%) and DG2 (10.5%), followed by 
decreasing fractions of directionality at DG3 (9.8%), DG4 (2.2%), and DG5 (3.3%).
In addition, Wind-Rose plots display the average maximum cell path length, PL, of motile 
cells tracked along the entire microchannel. Using this data, 32% of motile MB migrated 
distances greater than 200 microns (or 20 cell-diameters) when exposed to EGF gradient 
fields, as seen in Figure 5.B. By contrast, 97.3% of cells exposed to SDF-1 gradients 
migrated distances less than 200 microns. MB within our μLane system in the absence of 
growth factors or concentration gradients (i.e. controls) displayed migration distances 
between 50 and 200 microns (14). As shown, increasing percentages of cells were seen to 
migrate in response to higher gradient fields of EGF. A larger percentage of motile MB were 
observed in response to G1 fields of EGF at every distance, while only cells exposed to G1 
migrated the longest distances greater than 300 microns. In comparison, MB exposed to 
lower gradient fields of SDF-1 (G3-G5) exhibited the longest migration. Notably, zero cells 
were observed to migrate less than 100 microns when exposed to any EGF gradient field G1-
G5, while zero cells were seen to migrate greater than 300 microns when exposed to any 
SDF-1 gradient fields G1-G5.
DISCUSSION
The chemotactic migration of MB-derived cells has been surprisingly understudied despite 
its well-known metastatic potential and aggressive invasion into the brain and spinal 
cord (14, 43). Our study is among the first to examine and compare the migratory responses of 
MB to dosage-dependent signaling from EGF, HGF, PDGF-BB, and SDF-1, the most 
widely-acknowledged chemoattractants of CNS tumor cells (37). The first set of experiments 
utilized conventional transwell assays to illustrate that MB migration was most 
concentration-dependent to EGF signaling. As shown in Figure 1, MB exhibited dosage-
dependent migration in response to signaling from EGF and HGF, but seemingly dosage-
independent responses to PDGF and SDF-1 signaling. Further, EGF simulated the migration 
of approximately twice the number of MB cells than did PDGF, HGF, or SDF-1. Results 
from immunocytochemistry support the strength of MB chemotactic response to EGF 
signaling, as activation of its receptor, EGF-R, was two times larger than activation of other 
respective receptors. While strong MB chemotactic response to EGF signaling is consistent 
with previous findings from our group and others (14, 42), it is most significant here because 
it is signaling from SDF-1, rather than EGF, that has been reported as the strongest MB 
chemoattractant (56). Inhibitor AMD310, which cleaves CXCR4, has been reported to 
decrease MB tumor growth in mouse xenografts, chemotaxis and proliferation (56). 
However, in vivo use of EGF-R inhibitors such as Tarceva and Gefitinib have reported no 
changes in motility of cells derived from glioma (47), and non-small-cell lung cancer (23), 
and thus, were minimally used on MB. We contend that MB chemotactic response may not 
have been measured most meaningfully in the past, which has stymied development of anti-
migratory therapies for MB metastasis. For this reason, we used microfluidic systems to 
more precisely study MB migratory responses using parameters relevant to metastasis.
Using the μLane system, we were able to image real-time cell behavior in response to a wide 
range of concentrations and gradients of EGF and SDF-1, and distinguish directed-migration 
Rico-Varela et al. Page 9













of chemotaxis. MB migratory behavior was observed to be concentration gradient-dependent 
for both EGF and SDF-1 signaling, as the fraction of motile cells decreased with decreasing 
concentration gradient in both cases. However, motile MB traveled longer distances within 
the μLane in response to EGF signaling, with an average PL of 264.5 ± 67.8 μm, compared 
to an average PL of 125.5 ± 48.6 μm when responding to signaling from SDF-1. Further, 
cell trajectories illustrated an MB directional bias towards decreasing EGF gradients not 
present with SDF-1 signaling, with 18.3% of cells migrating towards decreasing EGF 
gradients compared to 15.3% of MB in response to decreasing SDF-1 gradients. 
Importantly, this behavior was observed along the entire μLane length, for cells exposed to 
all concentration gradient fields, G1-5. Here, the cell directionality compared to other 
methods provides insight into whether MB cells stimulated with ligand solutions (EGF or 
SDF-1) followed a directional migration along gradient fields. Other methods to measure 
cell migration include the persistence length and average velocity to determine the 
chemotactic sensitivity of stable gradients in 3D (22, 46, 72, 75). While the persistence length 
provides the ratio of the net distance traveled to the total distance, it would not report the 
number of cells that migrate along ligand concentration gradients, which is highly 
significant to studies developing migration-targeted therapies for tumors of the CNS.
This consistent MB behavior illustrates that EGF signaling from high concentration 
gradients initiates the most motile MB, and further enables cells to travel the longest 
distances. MB cells were seen to migrate towards increasing ligand concentration, which 
also corresponds to decreasing EGF gradient fields in our system. This response is 
significant because it reflects MB sensitivity to high concentration gradients (G1-G2), which 
were generated via much greater nonlinear changes in ligand concentration as compared to 
low gradient fields (G3-G5). Previous work from our group has illustrated keen abilities of 
MB to migrate in larger numbers in response to increasing EGF concentration via pERK 
signaling (14). In that work, MB cells were seen to travel out of a cell reservoir when 
exposed to increasing gradients and concentration. In the current study, we now demonstrate 
that MB can become less motile when exposed to signaling from increasing concentration 
but diminishing EGF gradient fields.
Data from the current study highlights the high fraction of motile MB in response to high 
concentration gradients of EGF. These results have high clinical interpretation, as they point 
to high gradient fields and low concentration fields as optimal for MB migration. This is an 
in-vivo scenario where paracrine signaling from neighboring cells initiate the most MB 
migration, such that cell displacement diminishes as cells approach the signaling source, 
where gradients are low and concentration is high. In addition, our findings may aid clinical 
development of anti-migratory therapeutics with the potential to inhibit MB metastasis along 
the spinal column via EGF signaling.
CONCLUSION
In summary, our results illustrate that MB migration is both concentration and concentration 
gradient-dependent in response to EGF signaling. Further, our findings illustrate that high 
gradient fields of EGF result in the largest number of motile cells, which travel long 
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distances, and in a highly directional manner towards decreasing EGF gradients. These 
findings point to EGF as a viable molecule for migration-targeted therapies for MB.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Migration of MB-derived cells to different concentrations of selective chemotactic 
ligands
(A1) Schematic of transwell assay with motile cells attached to the underside of the porous 
membrane. (A2) Stained nuclei and cytoplasm of motile MB-derived cells toward different 
concentrations of (B1) EGF, (B2) HGF, (B3) PDGF, and (B4) SDF-1. The control groups 
indicate number of cells that migrated towards serum-free medium. An asterisk (*) indicates 
statistically significant data with p-values <0.05 against control group.
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Figure 2. Receptor activation within motile MB-derived cells
Immunocytochemistry of basal receptor expression of MB cells without ligand stimulation 
to (A1) EGF, (B1) SDF-1, (C1) HGF, and (D1) PDGF-BB. Receptor activation post-
stimulation with (A2) EGF, (B2) SDF-1, (C2) HGF, and (D2) PDGF-BB. The expression 
level of receptor following ligand stimulation of (A3) EGFR, (B3) CXCR4, (C3) c-Met, and 
(D3) PDGFR-BB normalized to basal control levels. Scale bars are 100μm. An asterisk (*) 
indicates statistically significant data with p-values <0.05.
Rico-Varela et al. Page 17













Figure 3. The μLane system and MB migratory responses
(A) Schematic of the bridged μLane system, showing cells inserted within the sink (SKR) 
and source (SRR) reservoir, and adhered along the microchannel. Chemotactic agents (e.g. 
EGF, SDF-1) are loaded into the source chamber (SRC), and transported to SKR to reach 
steady-state concentration distribution. (B) Top view image of the first layer PDMS bonded 
onto a glass slide. Two 9-nL reservoirs are connected by a microchannel of 13mm in length 
and 100μm in diameter. (C) Top view image of second layer PDMS bonded to the first 
layer. The source (SRC) and sink (SKC) chambers are connected by a bridge channel. (D) 
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Raw data image of motile MB cells within μLane system at (D1) source reservoir, (D2) mid 
channel, and (D3) sink reservoir.
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Figure 4. Concentration distribution along μLane and number of motile cells
(A) Concentration profile of EGF and SDF-1 along 13-mm microchannel length of μLane 
system. Concentration gradients are identified by five orders of magnitude in the 
microchannel: 10+1<G1<100 ng/(mL.mm), 100<G2<10−1 ng/(mL.mm), 10−1<G3<10−2 ng/
(mL.mm), 10−2<G4<10−3 ng/(mL.mm), and 10−3<G5<0 ng/(mL.mm). (B) Fraction of MB-
derived cells observed to respond via migration to the different concentration gradient fields 
(G1 through G5) of EGF and SDF-1.
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Figure 5. Motility of MB-derived cells in the μLane system
(A) Representative trajectories of cells that migrated in response to 100ng/mL of EGF and 
100 ng/mL of SDF-1 stimulation. Three cell paths are shown in dashed for EGF and three in 
solid for SDF-1, 24 hours post steady-state. Note that concentration gradients decrease from 
left to right within the μLane. (B) Maximum accumulated distance of motile cells stimulated 
by concentration profiles generated by using 100ng/mL of EGF and 100 ng/mL of SDF-1, 
respectively, in the SRR of the μLane.
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Growth Factors 0 ng/mL [Mean ± 
SD cells]
1 ng/mL [Mean ± SD 
cells]
10 ng/mL [Mean ± 
SD cells]
100 ng/mL [Mean ± 
SD cells]
1000 ng/mL [Mean ± 
SD cells]
EGF 102 ± 5 * 156 ± 5 212 ± 7 174 ± 5
SDF-1 60 ± 2 67 ± 6 69 ± 14 72 ± 5 74 ± 4
HGF 99 ± 5 126 ± 10 160 ±13 122 ± 7 *
PDGF-BB 82 ± 5 83 ± 5 93 ± 8 100 ± 5 *
1
Average numbers of MB-derived cells that migrated in transwell assays towards different concentrations of examined growth factors. Values were 
experimentally measured and are shown with mean and standard deviation.
*
denotes growth factor concentrations not measured in the current study.
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Table 2
Summary of migration parameters for EGF and SDF-1.
2
Migration Parameters EGF SDF-1
Fraction of motile cells (f) [%] 72.8% 67.3%
Cell Directionality (D) [%] 61.6% 44.2%
Average Maximum Cell Path Length (PL) in μm [Mean ± SD] 264.5 ± 67.9 μm 125.5 ± 48.6 μm
2
Migratory parameters of MB-derived cells along the μLane system in response to concentration gradients generated by 100ng/mL of EGF and 100 
ng/mL of SDF-1, respectively. Values were experimentally measured and shown as percentages, means and standard deviations. (ncells ~ 180 cells 
for each ligand).
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